Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06430788 · ClinicalTrials.gov registry record · Phase 2
A Study of Emapalumab for Pediatric Aplastic Anemia
A Phase 2 study of Aplastic Anemia and Cytopenia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT06430788: Recruiting Phase 2 study of Aplastic Anemia and Cytopenia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06430788 is a Phase 2 study of Aplastic Anemia and Cytopenia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (15% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06430788, a Phase 2 study of Aplastic Anemia and Cytopenia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Primary Outcome
The primary objective of the study is to assess the efficacy of early upfront emapalumab on hematologic recovery within 6 weeks of starting therapy after a new diagnosis of Aplastic Anemia. Response will be determined by blood count.
Conditions Studied
Interventions
- BIOLOGICAL Emapalumab
Study Locations (6)
Wisconsin
- Children's Hospital of Wisconsin (Data Collection Only) - Milwaukee
- Medical College of Wisconsin (Data Collection AND Data Analysis) - Milwaukee
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Ohio
- Cincinnati Children's Hospital Medical Center (Data collection only) - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis) - Philadelphia
Virginia
- Virginia Commonwealth University (Data Collection Only ) - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2029-05-21 |
| Phase | Phase 2 |
What NCT06430788 shows while recruiting
NCT06430788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (15% lower).
The record links to 3 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Emapalumab is the first listed.
NCT06430788 lists 6 locations in 5 states (Wisconsin, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT06430788 about?
NCT06430788 is a clinical study titled "A Study of Emapalumab for Pediatric Aplastic Anemia". The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
What is the current status of trial NCT06430788?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-05-21. Estimated completion is 2029-05-21.
What conditions does trial NCT06430788 study?
This clinical trial studies the following conditions: Aplastic Anemia, Cytopenia, Hypocellular Marrow.
What interventions are being tested in trial NCT06430788?
The interventions under investigation include: Emapalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06430788?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06430788 being conducted?
This trial has 6 study locations across New York, Ohio, Pennsylvania, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06430788's enrollment target sits among peer trials
35 11th of 23 higher than 13 of 23 other Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
RECRUITING · Phase 2
-
Haploidentical HCT for Severe Aplastic Anemia
RECRUITING · Phase 2
-
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI